MaxCyte (MXCT) said Thursday it has acquired SeQure Dx for $4.5 million in upfront cash and up to $2.5 million in contingency payments.
SeQure Dx provides on-target and off-target editing assessment services for cell and gene therapies.
MaxCyte expects the deal to be accretive to its revenue growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.